title: [A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel].
abstract: We report a patient with far-advanced gastric cancer treated by weekly administration of paclitaxel (TXL) over 2 years. The patient was a 66-year-old female with peritoneal metastasis and remarkable lymph node metastasis of scirrhous gastric cancer. She underwent a non-curative resection with total gastrectomy and splenectomy in May 2002. Postoperative chemotherapy with TS-1 (80 mg/body) was performed. Due to grade 4 neutropenia and grade 2 anorexia, this treatment could not be continued. Three months after surgery, the tumor marker (CA19-9) had elevated to an abnormal level. Alternatively, TXL was administered at a weekly dose of 70 mg/m2 for 3 weeks followed by 6 weeks rest from September 2002. The tumor marker (CA19-9) gradually decreased to the normal level. Because of the long rest interval, 10 courses of treatment could be continued, and the patient has been alive over 2 years with the cancer controlled. There have been few effective chemotherapies for gastric cancer with peritoneal metastasis. Weekly paclitaxel therapy is considered to be effective for the treatment of advanced scirrhous gastric cancer with peritoneal metastasis.
authors.affiliation: Dept. of Surgery, Chiba Medical Center, National Hospital Organization.
authors.forename: Koya
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Tazawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Suzuki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Aoki
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Shiramatsu
authors.forename: Jun
authors.initials: J
authors.lastname: Kobayashi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Morishima
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Toyoda
authors.forename: Tadaomi
authors.initials: T
authors.lastname: Fukada
authors.forename: Kentaro
authors.initials: K
authors.lastname: Horiguchi
authors.forename: Kaisuke
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nakano
authors.forename: Masaru
authors.initials: M
authors.lastname: Miyazaki
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D017239:Paclitaxel / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000556:secondary; D011788:Quality of Life; D013156:Splenectomy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017741:Survivors
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel